Exact Mass: 649.3039

Exact Mass Matches: 649.3039

Found 25 metabolites which its exact mass value is equals to given mass value 649.3039, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

nigellamine A1

nigellamine A1

C40H43NO7 (649.3039)


   

Lys Met Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C33H43N7O5S (649.3046)


   

Lys Trp Met Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid

C33H43N7O5S (649.3046)


   

Lys Trp Trp Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C33H43N7O5S (649.3046)


   

Met Lys Trp Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C33H43N7O5S (649.3046)


   

Met Trp Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C33H43N7O5S (649.3046)


   

Met Trp Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C33H43N7O5S (649.3046)


   

Trp Lys Met Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid

C33H43N7O5S (649.3046)


   

Trp Lys Trp Met

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C33H43N7O5S (649.3046)


   

Trp Met Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C33H43N7O5S (649.3046)


   

Trp Met Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C33H43N7O5S (649.3046)


   

Trp Trp Lys Met

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-4-(methylsulfanyl)butanoic acid

C33H43N7O5S (649.3046)


   

Trp Trp Met Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]hexanoic acid

C33H43N7O5S (649.3046)


   

PCTR1

16R-(S-glutathionyl)-17S-hydroxy-4Z,7Z,10Z,12E,14E,19Z-docosahexaenoic acid

C32H47N3O9S (649.3033)


   

MCTR1

13R-(S-glutathionyl)-14S-hydroxy-4Z,7Z,9E,11E,16Z,19Z-docosahexaenoic acid

C32H47N3O9S (649.3033)


   

vicriviroc maleate

vicriviroc maleate

C32H42F3N5O6 (649.3087)


C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist

   

Fmoc-NH-PEG8-CH2COOH

Fmoc-NH-PEG8-CH2COOH

C33H47NO12 (649.3098)


   
   

(4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-14-hydroxydocosa-4,7,9,11,16,19-hexaenoic acid

(4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-14-hydroxydocosa-4,7,9,11,16,19-hexaenoic acid

C32H47N3O9S (649.3033)


   

L-gamma-glutamyl-S-[(3Z,6R,7S,15Z,18Z)-21-carboxy-6-hydroxyhenicosa-3,8,10,12,15,18-hexaen-7-yl]-L-cysteinylglycine

L-gamma-glutamyl-S-[(3Z,6R,7S,15Z,18Z)-21-carboxy-6-hydroxyhenicosa-3,8,10,12,15,18-hexaen-7-yl]-L-cysteinylglycine

C32H47N3O9S (649.3033)


   

(13R)-S-glutathionyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid

(13R)-S-glutathionyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid

C32H47N3O9S (649.3033)


A docosanoid that is (14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which a glutathionyl group is attached at position 13R via a sulfide linkage.

   

16(S)-glutathionyl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid

16(S)-glutathionyl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid

C32H47N3O9S (649.3033)


A docosanoid that is 17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid in which a glutathionyl group is attached at position 16S via a sulfide linkage. An intermediate of specialised proresolving mediators.

   

ST 25:5;O7;HexNAc

ST 25:5;O7;HexNAc

C33H47NO12 (649.3098)


   

11-(benzoyloxy)-12-[(benzoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

11-(benzoyloxy)-12-[(benzoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

C40H43NO7 (649.3039)


   

(1s,2r,4s,6r,9e,11s,12s)-11-(benzoyloxy)-12-[(benzoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

(1s,2r,4s,6r,9e,11s,12s)-11-(benzoyloxy)-12-[(benzoyloxy)methyl]-4,9-dimethyl-15-(propan-2-ylidene)-5-oxatricyclo[10.3.0.0⁴,⁶]pentadec-9-en-2-yl pyridine-3-carboxylate

C40H43NO7 (649.3039)